pb1023
Recombinant proteinexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2010 (NCT01236404)
Timeline
Indications
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314983 ↗
Also known as
- pb1023
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05833711 | Phase 2 | Sep 5, 2023 | Immunoforge Co. Ltd. |
| NCT01658501 | Phase 2 | Jul 1, 2012 | PhaseBio Pharmaceuticals Inc. |
| NCT01427257 | Phase 1 | Feb 1, 2012 | PhaseBio Pharmaceuticals Inc., Prism Research |
| NCT01478399 | Phase 1 | Dec 1, 2011 | PhaseBio Pharmaceuticals Inc., Prism Research |
| NCT01236404 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2010 | PhaseBio Pharmaceuticals Inc., Prism Research |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PhaseBio Pharmaceuticals Inc. | For profit | 4 | 4 | 2 | 2010 |
| Prism Research | For profit | 3 | 0 | 2 | 2010 |
| Immunoforge Co. Ltd. | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1